Heart disease and erythropoietin

Future Cardiology

Volumn 4, Issue 1, 2008, Pages 57-64

  Rao, K Nayan S ^a,b   Binbrek, Azan S ^a   Sobel, Burton E ^c  

^a RASHID HOSPITAL   (United Arab Emirates)

^b DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

Acute coronary syndrome; Apoptosis; Erythropoietin; Heart failure; Myocardial infarction; Myocardial ischemia; Neovascularization; Reperfusion; Tissue protection

Indexed keywords

ANTIANEMIC AGENT; CREATINE KINASE; ERYTHROPOIETIN; ERYTHROPOIETIN ALPHA; ERYTHROPOIETIN BETA; ERYTHROPOIETIN GAMMA; HEPARIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANEMIA; CARBAMOYLATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; ERYTHROPOIESIS; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEMATOCRIT; HEMATOPOIESIS; HUMAN; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE; THROMBOSIS;

EID: 38049110388     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.1.57     Document Type: Review

References (76)

1. Sobel BE, Dauerman HL: The rationale underlying pharmacoinvasive therapy. In: Pharmacoinvasive Therapyin Acute Myocardial Infarction. Sobel BE, Dauerman HL (Eds). Taylor & Francis Group, NY, USA 3-32 (2005).
2. Gogo P, Dauerman HL, Sobel BE: Prompt reperfusion: the linchpin of treatment for ST elevation myocardial infarction (STEMI). In: Cardiac Intensive Care (2nd Edition). Brown D, Jeremias A (Eds). Elsevier Publishers, Philadelphia, PA, USA (2007) (In press).
3. Yusuf S, Hawken S, Ounpuu S et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEAET study): case-control study. Lancet 364, 937-952 (2004).
4. Chance B: Pyridine nucleotide as an indicator of the oxygen requirements for energy-linked functions of mitochondria. Circ. Res. 38, I-31-I-38 (1976).
5. Jennings RB: Relationship of acute ischemia to functional defects and irreversibility. Circulation 53, I-26-I-29 (1976).
6. Sobel BE, Shell WE: Jeopardized, blighted, and necrotic myocardium. Circulation 47, 215-216 (1973).
7. Sobel BE, Zaman AKMT, Budd RC, Schneider DJ, Taatjes DJ: Attenuation of apoptosis and the eye of the beholder. Coron. Artery Dis. (2007) (In Press).
8. Davidson SM, Hausenloy D, Duchen MR, Yellon DM: Signalling via the reperfusion injury signaling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J. Biochem. Cell Biol. 38(3), 414-419 (2006).
9. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N. Engl. J. Med. 357(11), 1121-1135 (2007).
10. Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: united at reperfusion. Pharmacol. Ther. 116(2), 173-191 (2007).
11. Ambros JT, Herrero-Fresneda I, Borau OG, Boira JM: Ischemic preconditioning in solid organ transplantation: from experimental to clinics. Transpl. Int. 20(3), 219-229 (2007).
12. Joyeux-Faure M: Cellular protection by erythropoietin: new therapeutics implications? J. Pharmacol. Exp. Ther. 323(3), 759-762 (2007).
13. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim. Biophys. Acta 1776(1), 1-9 (2007).
14. Mennini T, DePaola M, Bigini P et al.: Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol. Med. 12(7-8), 153-160 (2006).
15. Gorio A, Gokmen N, Erbayrktar S et al.: Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc. Natl Acad. Sci. USA 99, 9450-9455 (2002).
16. Moon C, Krawczyk M, Ahn D et al.: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl Acad. Sci. USA 100, 11612-11617 (2003).
17. Parsa CJ, Matsumoto A, Kim J et al.: A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112. 999-1007 (2003).
18. Fiordaliso F, Chimenti S, Staszewsky L et al.: A nonerythropoietic derivative of erythropoietin protects the myocardiuim from ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 101, 2046-2051 (2005).
19. Calvillo L, Latini R, Kajstura J et al.: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 100, 4801-4806 (2003).
20. Lipsic E, Shoemaker RG, van der Mer P, Voors AA, van Veldhuisen DJ, van Gilst WH: Protective effects of erythropoietin in cardiac ischemia, from bench to bedside. J. Am. Coll. Cardiol. 48, 2162-2167 (2006).
21. Hirata A, Minamino T, Asanuma H et al.: Erythropoietin enhances neovascularization of Ischemia myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardiol. 48, 176-184 (2006).
22. Schneider C, Jaquet K, Malisius R et al.: Attenuation of cardiac remodeling by endocardial injection of erythropoietin: Ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur. Heart J. 28, 499-509 (2007).
23. Brines ML, Ghezzi P, Keenan S et al.: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 97, 10526-10531 (2000).
24. Wang L, Zhang Z, Wang Y et al.: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35, 1732-1737 (2004).
25. Shi Y, Raftee P, Su J et al.: Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 99, 173-182 (2004).
26. Anversa P, Cheng W, Liu Y, Leri A, Redaelli G, Kajstura J: Apoptosis and myocardial infarction. Basic Res. Cardiol. 93(Suppl. 3), 8-12 (1998).
27. Bahlmann FH, Song R, Boehm SM et al.: Low-dose therapy with the long-acting erythropoietln analogue darbepoeitin persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110, 1006-1012 (2004).
28. Nyolczas N, Gyongyosi M, Beran G et al.: Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) study: a multicenter, prospective, randomized, single-blind trial comparing early and later intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction. Am. Heart J. 153(2), 212. e1-e7 (2007).
29. Werner N, Kosiol S, Scheigi T et al.: Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
30. Bahlmann FH, De Groot K, Spandau JM et al.: Erythropoietin regulates endothelial progenitor cells. Blood 103, 921-926 (2004).
31. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM: Blood transfusion in elderly patients with acute myocardial infarction. N. Engl. J. Med. 345, 1230-1236 (2001).
32. Al Falluji N, Lawrence-Nelson J, Kostis JB, Lacy CR, Rarjan R, Wilson AC: Effect of anemia on 1-year mortality in patients with acute myocardial infarction. Am. Heart J. 144, 636-641 (2002).
33. Sabatine MS, Morrow DA, Giugliano R et al.: Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111, 2042-2049 (2005).
34. Reinecke H, Trey T, Wellmann J et al.: Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur. Heart J, 24, 2142-2150 (2003).
35. McKechnie RS, Smith D, Montoye C et al.: Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 110, 271-277 (2004).
36. Nikolsky E, Mehran R, Aymong ED et al.: Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am. J. Cardiol. 94, 1023-1027 (2004).
37. Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK: Anemia is an independent predictor of mortality after percutaneous coronary intervention. J. Am. Coll. Cardiol. 44, 541-546 (2004).
38. Nikolsky E, Aymong ED, Halkin A et al.: Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention - analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J. Am. Coll. Cardiol. 44, 547-553 (2004).
39. Yusuf S, Fox KAA, Tognoni G et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
40. Mehta SR, Yusuf S, Peters RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
41. Schneider DJ, Sobel BE: Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 116, 305-315 (2007).
42. Bindra K, Berry C, Rogers J et al.: Abnormal hemoglobin levels in acute coronary syndromes. QJM 99(12), 851-862 (2006).
43. Berry C, Norrie JN, Hogg K, Brett M, Stevenson K, McMurray JJV: The prevalence, nature and importance of hematologic abnormalities in heart failure. Am. Heart J. 151, 1513-1521 (2006).
44. Ishani A, Weinhandl E, Zhao ZH et al.: Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 45, 391-399 (2005).
45. Volpe M, Tritto C, Testa U et al.: Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic and hormonal profiles. Am. J. Cardiol. 74, 468-473 (1994).
46. Van der Meer P, Voors AA, Lipsic E, Smilde TDJ, Van Gilst WH, Van Veldhuisen DJ: Prognostic value of plasma erythropoietin on mortality in patients with congestive heart failure. Am. Coll. Cardiol. 44, 63-67 (2004).
47. Silverberg DS, Wexler D, Blum M et al.: Erythropoietin in heart failure. Semin. Nephrol. 25(6), 397-403 (2005).
48. Naimuchi S, Kagaya Y, Ohta J et al.: High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary interventinon J. Am. Coll. Cardiol. 45, 1406-1412 (2005).
49. Anton Martinez J, Ojeda Ortego J, Gonzalez Blanco P, Gutierrez Sampedro N, Palma Nieto JC, Leon Garcia LA: Increased levels of EPO in initial phase of acute myocardial infarction. An. Med. Interna. 14, 459-461 (1997).
50. Sarnak MJ, Tighiouart H, Manjunath G et al.: Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities(aric) study. J. Am. Coll. Cardiol. 40, 27-33 (2002).
51. Ezekowitz JA,McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insight from a cohort of 12065 patients with new-onset heart failure. Circulation 107, 223-225 (2003).
52. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the Prospective Amlodipine Randomized Survival Evaluation (PRAISE). J. Am. Coll. Cardiol. 41, 1933-1939 (2003).
53. Mancini DM, Katz SD, Lang CC, La Manca J, Hudaihed A, Androne A-S: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299 (2003).
54. Collins A: Discussion. Proceedings of the ASN Symposium. Doubletree Hotel, Tucson, AZ, USA, December 10 (2002).
55. Shu DH, Ransom TP, O'Connell CM et al.: Anemia is an independent risk for mortality after acute myocardial Infarction in patients with and without diabetes. Cardiovasc. Diabetol. 5, 8 (2006).
56. Rao SV, Jollis JG, Harrington RA et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292, 1555-1562 (2004).
57. Moon C, Krawczyk M, Paik D et al.: Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pbarmacol. Exp. Ther. 316(3), 999-1005 (2006).
58. Double-blind placebo-controlled study of the therapeutic use of recombinant human erythropoeitin for anemia associated with chronic renal failure in predialysis patients: the US Recombinant Human Erythropoietin Predialysis Study Group. Am. J. Kidney Dis. 18, 50-59 (1991).
59. Varet B, Casadevall N, Lacombe C, Nayeaux P: Erythropoietin and renin as biological markers in critically ill patients. Semin. Hematol. 27, 25-31 (1990).
60. Fuste B, Serradell M, Escolar G et al.: Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenecity of their extracellular matrixes in vitro. Thromb, Haemost. 88, 678-685 (2002).
61. Anagnostou A, Lee ES, Kessimian N et al.: EPO has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA 87, 5978-5982 (1990).
62. Wagner KF, Katschinski DM, Hasegawa J et al.: Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97, 536-547 (2001).
63. Stohlawetz PJ, Dzirlo L, Hergovich N et al.: Effects of erythropoietin on platelet reactivity and thrombopoeisis in humans. Blood 95, 2983-2989 (2000).
64. Lipsic E, van der Meer P, Henning RH et al.: Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharm. 44, 473-479 (2004).
65. Brown WM, Maxwell P, Graham AN et al.: EPO receptor expression in non-small cell lung cancer; a question of antibody specificity. Stem Cells 25, 718-722 (2007).
66. Ross SD, Allen IE, Probst CA. Sercus B, Crean SM, Ranganathan G: Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 12 (10), 1265-1273 (2007).
67. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI: Cardioprotection by recombinant human erythrpooietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc. Drugs Ther. 19(4), 243-250 (2005).
68. Moon C, Krawczyk M, Lakatta EG, Talan MI: Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc. Drugs Ther. 20(4), 245-251 (2006).
69. Shun D-H, Kwon Y-I, Choi S-I et al.: Accidental ten times overdose administration of recombinant human erythropoietin up to 318,000 units a day in AMI: report of two cases. Basic Clin. Pharmacol. Toxicol. 98, 222-224 (2006).
70. Lipsic E, van der Meer P, Voors AA et al.: A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20(2), 135-141 (2006).
71. Voors AA: University Medical Center Groningen(UMCG), Interuniversity Cardiology Institute (ICIN), The Netherlands: HEBE III: a prospective randomized, double blind, placebo controlled trial to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myocardial infarction. An ongoing multicenter study with 400 patients and an anticipated closing date of September 1 (2008).
72. Corwin HL, Gettinger A, Fabian TC et al.: Efficacy and safety of epoetin alfa in critically ill patients. N. Engl. J. Med. 357, 965-976 (2007).
73. Binbrek A, Rao N, Absher PM, Van de Werf F, Sobel BE: The relative rapidity of recanalization assessed by enzymatic methods. Coron. Artery Dis. 11, 429-435 (2000).
74. Binbrek A, Rao NS, Neimane D, Sobel BE: Comparison of rapidity of coronary recanalisation in men with TNK versus alteplase in AMI. Am. J. Cardiol. 93, 1465-1468 (2004).
75. Singh AK, Szczech L, Tang KL et al.: CHOIR Investigators. Correction of anemia with epotin alfa in chronic kidney disease. N. Eng.l J. Med. 355, 2085-2098 (2006).
76. Binbrek AS, Mettal B, Rao KNS, Sobel BE: The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron. Artery Dis. (2007) (In Press).